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Abstract 
 
Purpose: To investigate whether planning of pregnancy in women with epilepsy affects seizure 
control during pregnancy and to compare the maternal and neonatal outcomes in planned and 
unplanned pregnancies 
Methods: This was a retrospective cohort study of 153 pregnant women with epilepsy who were 
treated at the University of Tsukuba Hospital and Hokkaido University Hospital between 2003 
and 2011. Twenty-one pregnancies were excluded due to insufficient data. Data of patients 
followed by neurologists during their planned pregnancies (planned-pregnancy group, n = 51) 
were compared to those of patients referred to neurologists after conception for managing epilepsy 
during pregnancy (unplanned-pregnancy group, n = 81). The treatment profile for epilepsy, 
seizure control, and maternal and neonatal outcomes in both groups were compared using 
Chi-square test or Fisher’s exact test and Mann-Whitney U test. 
Results: Compared to the unplanned-pregnancy group, the planned-pregnancy group showed a 
significantly greater proportion of patients receiving monotherapy with antiepileptic drugs (80% 
vs. 61%: planned vs. unplanned, P = 0.049) and those not requiring valproic acid (77% vs. 56%, P 
= 0.031). Furthermore, the frequency of epileptic seizures (16% vs. 35%, P = 0.018) and changes 
in antiepileptic drugs (24% vs. 41%, P = 0.042) were significantly lower in the planned-pregnancy 
group than in the unplanned-pregnancy group. No significant intergroup differences were noted in 
the obstetric complications and neonatal outcomes, including congenital malformations.  
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Conclusion: For women with epilepsy, planning of pregnancy is associated with good seizure 
control during pregnancy and less fetal exposure to antiepileptic drugs.  
 
Key words 
 
Epilepsy, Planned pregnancy, Seizure control, Antiepileptic drugs, Monotherapy, 
Neonatal/maternal outcome 
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1) Introduction 
 
     Population-based studies indicate that the prevalence of epilepsy in pregnant women is 
0.7%, whereas registry-based studies suggest a range of 0.2－0.4%1. Thus, obstetricians often 
encounter cases of pregnancy in women with epilepsy (WWE1) and can be involved in the 
management of the pregnancies in these women as well as offer preconception counseling. In 
general, although the pregnancy outcomes in most WWE are favorable, epilepsy poses additional 
risks for the mother and fetus, including the potential effects of teratogenic antiepileptic drugs 
(AEDs2), the effects of maternal seizures on the fetus, and genetic risks, all of which contribute to 
a two- to three-fold increase in the risk of adverse outcomes2. These adverse outcomes include 
major congenital malformation (MCM3) in the fetus and long-term developmental delay.  
     A maternal seizure can directly affect the fetus and cause fetal hypoxia and distress. 
Additionally, adverse effects on the mother include falls; superficial abdominal hematomas; burns 
or other accidents; and significant obstetric sequelae, such as placental abruption and premature 
labor and delivery. Various complications of pregnancy have been reported in WWE. These 
women are at an increased risk of spontaneous abortion, induction of labor, cesarean section, and 
postpartum hemorrhage4. Infants of WWE exposed to AEDs in utero are at a high risk of fetal 
growth restriction, preterm birth, low birth weight, and low Apgar scores4. 
                                            
1 WWE: Women with epilepsy 
2 AED: Antiepileptic drug 
3 MCM: Major congenital malformation 
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     The incidence of fetal MCM in women without epilepsy is 1.6–2.2%5-7, whereas that in 
WWE is higher, at 2.8–3.6%8-10 who take AEDs and at 4.2–6.7% who do not take AEDs5, 6 8-10. 
Furthermore, the risk of fetal MCM increases with the number of AEDs administered6, 7, 10, 11. In 
particular, treatment with valproic acid (VPA4) in combination with AEDs is associated with a 
high risk of fetal MCM12. The teratogenic effects of most AEDs appear to be dose dependent8, 13, 
and numerous reports have confirmed this dose dependency in the case of VPA8, 10, 11, 14-16. Hence, 
transitioning from VPA to another AED should be considered before conception, and the lowest 
possible dose of the most appropriate AED should be administered before conception in WWE. 
     The Japanese guidelines for the management of WWE, as stipulated by the Societas 
Neurologica Japonica, recommend preconception counseling to provide detailed information 
about pregnancy and delivery in WWE and emphasize the importance of the medication during 
pregnancy, along with antenatal management involving the use of the lowest possible dose of the 
most appropriate AED, avoiding VPA, possibly withdrawing AED before conception, and 
supplementation with folic acid before and after conception to prevent neural tube defects17. 
International guidelines recommend monotherapy with lamotrigine owing to its low risk of 
teratogenicity; however, this treatment option is currently not permitted by the Japanese national 
health insurance policy17.  
     Although various guidelines recommend planned pregnancy for WWE, the effects of 
planning remain largely unclear. Preconception counseling for WWE has been reported to be 
                                            
4 VPA: Valproic acid 
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effective for reducing fetal MCM in children born to WWE receiving AEDs18. However, the 
effects of a planned pregnancy on seizure control in WWE during pregnancy and maternal and 
neonatal peripartum outcomes have not been evaluated; in the present study, we aimed to evaluate 
these effects. Moreover, we aimed to compare the maternal and neonatal outcomes in planned and 
unplanned pregnancies in WWE. 
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2) Methods 
 
     We retrospectively reviewed the hospital records of 153 pregnancies in WWE who were 
treated at the University of Tsukuba Hospital (98 pregnancies) and Hokkaido University Hospital 
(55 pregnancies) between 2003 and 2011. Planned pregnancy was defined as the completed 
process of planning and preparing for pregnancy, during which the doses and numbers of AEDs 
and maternal physical health prior to conception were optimized by neurologists or neurosurgeons. 
According to the Japanese Healthcare system, all WWE taking AEDs should be followed up by 
their neurologists or neurosurgeons and not by general physicians, even if their seizures are well 
controlled, and some WWE who remain free of seizures without taking AEDs for a long duration 
are normally not followed by any medical doctor. Among WWE in the planned-pregnancy group, 
those who were regularly reviewed by their neurologists or neurosurgeons before conception 
received preconception counseling, epilepsy reassessment, AED dose adjustment; after successful 
execution of the planned pregnancy processes, their neurologists or neurosurgeons considered 
their conception appropriate. For WWE in the planned-pregnancy group who were not followed 
by medical doctors, neurologists or neurosurgeons consulted their conception, reviewed their 
condition, and considered pregnancy to be appropriate. The unplanned-pregnancy group included 
all the pregnancies not included in the planned-pregnancy group. WWE in the unplanned 
pregnancy group who were regularly followed up by their neurologists or neurosurgeons included 
those with unexpected pregnancies (for both WWE and medical doctors) and those in whom the 
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pregnancy had occurred during planning but not when conception was considered appropriate by 
the neurologists or neurosurgeons. The unplanned pregnancy group also included pregnancies of 
WWE who were not followed up by medical doctors and who did not consult neurologists or 
neurosurgeons about their pregnancy before conception. The planned pregnancy process was 
recorded on their medical chart or the introduction form administered at our hospital. The 
pregnancy was planned according to the discretion of the neurologist or neurosurgeon and was not 
structured, but it was in accordance with the guidelines for doctors authorized to treat patients 
under the Japanese government medical insurance system, as well as with the Japanese guidelines 
for the standard management of epilepsy. Data regarding the history of preconception treatment 
were unavailable in the case of 21 pregnancies, including medical letters from neurologists or 
neurosurgeons and medical interview forms; hence, these pregnancies were excluded from the 
study analysis. We classified the remaining 132 pregnancies on the basis of whether the 
pregnancy was planned or unplanned and compared the seizure control in pregnancy and maternal 
and neonatal outcomes in the 2 groups. Data were analyzed using the Chi-square test or Fisher’s 
exact test and the Mann–Whitney U test, as appropriate. A P value of <0.05 was considered 
statistically significant.  
     The approval of the institutional review board and ethics committee was obtained at the 
University of Tsukuba Hospital (number: H23-62) and Hokkaido University Hospital (number: 
011-0133). Informed consent was obtained from all patients. 
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3) Results 
 
     The planned-pregnancy group consisted of 51 pregnancies (39%), whereas the 
unplanned-pregnancy group comprised 81 pregnancies (61%). 
 
Maternal backgrounds 
     Table 1 shows the patient demographics. Women in the planned-pregnancy group were 
significantly older (median age, 32 years; range, 17 － 42 years) than those in the 
unplanned-pregnancy group (median age, 28 years; range, 22－38 years; P = 0.012) (Table 1). The 
2 groups showed no significant difference with respect to parity and gravidity (Table 1). Most 
women in both groups were Japanese. None of the women in the 2 groups had health conditions 
that were likely to affect maternal and neonatal peripartum outcomes, such as diabetes mellitus, 
hypertension, and hyperthyroidism. Only 1 woman in the unplanned-pregnancy group had asthma, 
which was well controlled. None of the women in the 2 groups had exposure to other teratogens 
except AEDs. Eight women in each group were overweight (BMI > 25), and the difference 
between the 2 groups in the proportion of overweight patients was not statistically significant (P = 
0.32). Socio-economic statuses of the women in the 2 groups were not significantly different.  
 
Treatment profile for epilepsy 
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     Table 2 shows the epileptic treatments administered to the patients. Approximately 75% of 
WWE in both groups received some kind of AED during pregnancy. Compared to the 
unplanned-pregnancy group, the planned-pregnancy group showed a significantly higher 
proportion of WWE who received monotherapy with AEDs (P = 0.049). For monotherapy, 
phenobarbital (PB5) was the most common medication used in the planned-pregnancy group 
(10/31), followed by Carbamazepine (CBZ6) (8/31), VPA (8/31), clonazepam (3/31), diazepam 
(1/31), and primidone (1/31). In comparison, the primary drugs used for monotherapy in the 
unplanned-pregnancy group were VPA (17/37), CBZ (10/37), PB (3/37), phenytoin (PHT7) (3/37), 
clonazepam (2/27), clobazam (1/37), and zonisamide (1/37), in that order of frequency. Eight 
women required polytherapy in the planned-pregnancy group, of which 1 took VPA. In the 
unplanned-pregnancy group, 24 women required polytherapy, and 10 of them took VPA. VPA 
was required in significantly fewer cases in the planned-pregnancy group than in the 
unplanned-pregnancy group (9 vs. 27, P = 0.031). No significant intergroup difference was noted 
with regard to folic acid supplementation. 
 
Seizure control and AEDs during pregnancy 
 
     A significantly high rate of seizures during pregnancy was recorded in the 
                                            
5 PB: Phenobarbital 
6 CBZ: Carbamazepine 
7 PHT: Phenytoin 
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unplanned-pregnancy group than in the planned-pregnancy group (Table 3). Due to concerns of 
teratogenicity, changes in the AED schedule immediately after the diagnosis of pregnancy were 
required in 21 WWE who belonged to the unplanned-pregnancy group (Table 3). Of these 21 
WWE, 8 requested the change themselves, whereas in 13 WWE, the change was recommended by 
neurologists. Eleven women (52.4%) had seizures even after altering the AED schedule. In 
particular, the rate of seizures was high (66.7%) in 12 women who took VPA before alteration of 
the AED schedule after pregnancy detection. With regard to these 12 women, seizures were noted 
in 1 of 3 women for whom VPA was switched to other AEDs, 1 woman whose VPA dosage was 
reduced, and 6 of 8 women for whom VPA was discontinued. 
     The rate of non-compliance with the AED treatment schedule was higher in the 
unplanned-pregnancy group than in the planned-pregnancy group (Table 3). In the 
planned-pregnancy group, 3 women opted to discontinue AEDs before conception of their own 
accord and then resumed these medications after completion of the high-risk period of fetal 
malformations according to the recommendations of their neurologists. They did not experience 
any seizure during the AED-free period. In the unplanned-pregnancy group, 13 women 
discontinued AEDs by themselves after the detection of pregnancy. Eight of them subsequently 
experienced seizures, which made it necessary to restart AED treatment, but 1 WWE refused to 
resume the AED treatment despite developing seizures. Of the remaining 5 women without 
seizures, 4 resumed AED treatment after the teratogenic period, whereas 1 did not resume AED 
treatment throughout the pregnancy, as per the advice of the neurologist.  
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     The percentage of patients receiving stable antiepileptic treatment, i.e. no change in the type 
and dosage of AEDs or no additional requirement of AEDs, and was significantly higher in the 
planned-pregnancy group than in the unplanned-pregnancy group (Table 3). In the 
planned-pregnancy group, 12 women required medication adjustment, and all of them required an 
increase in the dosage of AEDs because of seizures (6/12), abnormal electroencephalogram 
findings (2/12), or for restarting previously withdrawn AEDs after the organogenetic period (4/12). 
In comparison, 33 women in the unplanned-pregnancy group required alterations in the AED 
schedule during pregnancy; the changes were required because of pregnancy detection in 21 of 
these women and because of seizures (increased dosage, 10 women) or for unknown reasons 
(increased dosage, 2 women) in 12 of them. 
  
Peripartum outcomes  
 
    Peripartum outcomes are shown in Table 4. There was no significant difference in the 
frequency of preterm birth between the 2 groups (4/51 in planned vs. 8/81 in unplanned, P = 0.77). 
Similarly, no significant differences were noted in the frequency of termination of pregnancy and 
the modes of delivery. 
 
Neonatal outcomes  
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     Table 5 shows the neonatal outcomes. There was no significant difference in the birth 
weight and Apgar scores of the live-born neonates between the planned- and 
unplanned-pregnancy groups. The rates of congenital malformations were nearly identical in the 2 
groups. In the planned-pregnancy group, the congenital malformations included 2 cases of 
ventricular septal defects (VSDs 8 ), 1 case of cryptorchidism, and 1 case of congenital 
diaphragmatic eventration. Exposure to AEDs in utero was noted in 2 cases: one infant with VSD 
was exposed to VPA (600 mg) and clonazepam (10 mg), whereas the one with cryptorchidism 
was exposed to CBZ (400 mg). In the unplanned-pregnancy group, 6 neonates had congenital 
anomalies, with 1 case each of fetal hydantoin syndrome (exposure to VPA [500 mg], PB [30 mg], 
and PHT [100 mg]), stenosis of the external acoustic meatus (exposure to VPA [800 mg] and PB 
[90 mg]), choroid plexus cyst (exposure to PB [60 mg]), hypotonia with widely spaced nipples 
(exposure to VPA [400 mg]), duodenal atresia with hypospadias (no AED exposure), and VSD 
(no AED exposure). There was no significant intergroup difference in the neonatal complications.  
                                            
8 VSD: ventricular septal defect 
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4) Discussion 
 
     In the present study, we investigated whether planned pregnancy in WWE affected seizure 
control in pregnancy and improved maternal and neonatal outcomes. We found that planning a 
pregnancy with alterations in the treatment regimen based on the currently accepted guidelines 
reduced the frequency of seizures during pregnancy and fetal exposure to AEDs, but did not 
significantly improve the maternal or neonatal outcomes. 
     Compared to the unplanned-pregnancy group, the planned-pregnancy group had a 
significantly higher rate of monotherapy and lower rate of VPA use, which reflects the clinical 
practice of the treating neurologists in adjusting the lowest possible dose of the most appropriate 
AED and switching from VPA to another AED according to the currently followed guidelines. 
Furthermore, compliance to medication was greater in the planned-pregnancy group than in the 
unplanned-pregnancy group; this may be partly attributed to the fact that the mothers were 
provided precise information about the risks of AEDs for the fetus and the necessity of taking 
AEDs to control seizure during the preconception counseling. Three women in the 
planned-pregnancy group chose to discontinue AEDs before conception, but restarted the AEDs 
according to the advice of their neurologists. Thus, preconception counseling and the active 
involvement of neurologists play important roles in improving seizure control in WWE during 
pregnancy. 
     In 21 cases in the unplanned-pregnancy group, the woman or the neurologist attempted to 
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change AEDs (5/21), decrease the dose of AEDs (5/21), or discontinue the AEDs (11/21) 
immediately after the detection of pregnancy because of concerns regarding the teratogenicity of 
AEDs, which led to seizures in 11 cases (52.4%). Seizures after changing the treatment schedule 
occurred particularly in women who had been taking VPA (66.7%). These cases were only 
observed in the unplanned-pregnancy group; it is possible that the seizures would have been 
avoided and the fetal exposure to AEDs would be minimized if the AEDs had been adjusted 
before conception in a carefully planned manner. If these 11 women had not had seizures, the rate 
of seizures during pregnancy in the unplanned-pregnancy group would be reduced to 21.0%, 
which is nearly equal to that in the planned-pregnancy group. Moreover, the absence of 
preconception counseling may have led to the non-compliance to AED intake noted in 13 women 
in the unplanned-pregnancy group, 8 of whom experienced seizures (61.5%). The non-compliance 
and subsequent occurrence of seizures may have been prevented if these women had received 
appropriate preconception counseling. We would like to emphasize that adjusting medications for 
reducing teratogenicity of fetuses during pregnancy poses a risk of inducing maternal epileptic 
seizures. 
     A decrease in the doses of AEDs during pregnancy was required only in the 
unplanned-pregnancy group. Pregnancy may reduce the plasma concentrations of AEDs19, and 
therefore, any dose adjustment that is required, usually involves increasing the concentration of 
AEDs as the pregnancy progresses. Since this may be counterintuitive to the natural physiology of 
pregnancy, the neurologists may reduce the AED dose in an unplanned pregnancy, as observed in 
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5 cases in this study. The occurrence of pregnancy may have been so unexpected in these cases 
that the doses of AEDs were decreased to reduce possibility of congenital malformation of fetuses. 
These changes resulted in a high rate of seizures, with 40% of these women subsequently 
experiencing seizures. Although the exact reasons for decreasing the dose of AEDs are unknown, 
we recommend a decrease in the dose before conception in cases where pregnancy is planned. 
     There were several limitations to this study. We focused on seizures during pregnancy, and 
the type of seizure and its direct impact on fetal or maternal outcomes were beyond the scope of 
this investigation. Nevertheless, we noted that epileptic seizures warranted termination of 
pregnancy in 2 cases among the planned-pregnancy group and in 5 cases in the 
unplanned-pregnancy group. Furthermore, cesarean delivery was performed in the 
unplanned-pregnancy group due to uncontrollable seizures (Table 4). The unplanned-pregnancy 
group had a higher rate of seizures during pregnancy and required more obstetric interventions 
due to epileptic seizures than the planned-pregnancy group. Thus, a planned pregnancy may result 
in reduced seizure activity and consequently require fewer obstetric interventions, such as 
termination of pregnancy or cesarean delivery. This study is retrospective in nature, and the 
women seeking preconceptional counseling are different from those with unplanned pregnancies.  
     The primary objective of a planned pregnancy in WWE is to avoid the use of AEDs, 
including VPA, which pose high teratogenic risks. In the present study, although VPA could be 
avoided in a significantly greater proportion of women in the planned-pregnancy group than in the 
unplanned-pregnancy group, the rate of congenital malformations in the 2 groups was similar. 
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This may be explained by the following 2 possibilities. First, the other AEDs are also teratogenic, 
and therefore, even if VPA is switched with another AED, not all congenital malformations can be 
prevented. A recent study on live-born infants revealed that exposure to new-generation AEDs, 
such as lamotrigine, oxcarbazepine, topiramate, gabapentin, and levetiracetam, during the first 
trimester was not associated with an increased risk of major birth defects20. If older AEDs could 
be switched to newer AEDs before conception in a planned pregnancy, then it may be possible to 
decrease the risk of developing congenital malformations. Second, our hospitals are general 
perinatal medical centers. Many fetuses with congenital malformations diagnosed on antenatal 
ultrasonography are referred from nearby clinics and hospitals to our centers, and incidental 
detection of epilepsy in such cases may skew the results of this study. At our hospitals, the 
incidence of MCM is 10.7% of all deliveries, which is much higher than the incidence 
(1.6–2.2%)5-7 in the general population and also higher than the percentage of fetuses exposed to 
AEDs (4.2–6.7%)5, 6, 8-10. Hence, this institutional bias limits our study findings on fetal congenital 
malformations. 
     Although a greater proportion of WWE in the planned pregnancy group received 
monotherapy of AEDs and required less VPA than the unplanned pregnancy group, possibly 
because of the adjustments made to AED dosage by neurologists or neurosurgeons, folate 
prescription levels were the same in the 2 groups. The situation on the supplementation of folic 
acid for women of the reproductive age in Japan may be related to these results. Folic acid intake 
from the Japanese diet is appropriate and neural tube defects in Japan are less frequent than that in 
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the other countries21. Therefore, the awareness of folic acid supplementation for women of 
reproductive age among medical doctors, even among the obstetricians, are lower in Japan than 
that in countries in Europe or Oceania as well as in other Asian countries, such as Korea or 
Taiwan, despite promotion by Japanese Ministry of Health, Labour and Welfare22. Because of 
these factors, neurologists or neurosurgeons may be less aware of folic acid supplementation for 
WWE in the planned pregnancy process, which may influence the results. Furthermore, we 
analyzed only WWE receiving folate prescription of 5 mg/day in the present study, and not WWE 
receiving over-the-counter drugs of folate supplementation (0.4 mg/day), which may also 
influence our results.
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5) Conclusions 
     In WWE, planned pregnancy is associated with good seizure control during pregnancy and 
less fetal exposure to AEDs. In cases of unplanned pregnancy, the doses of AEDs are adjusted 
immediately after pregnancy is determined, which results in a higher rate of seizures during 
pregnancy. Although we noted that planned pregnancy may also improve maternal and neonatal 
peripartum outcomes, we were unable to confirm this finding in the present study. 
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Table 1: Maternal characteristics 
 
 Planned Unplanned P value 
Number 51 81  
Age 17－42 22－38 0.012a 
Nullgravida 20 (39.2%) 37 (45.7%) 0.47 
Nullipara 29 (56.9%) 53 (65.4%) 0.32 
BMI 16.9－38.3 14.3－32.8 0.15 
Japanese 49 (96.1%) 79 (97.5%) 0.64 
On welfare 1 (2.0%) 4 (4.9%) 0.65 
 
aP < 0.05, BMI: Body mass index 
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Table 2: Treatment profile for epilepsy 
 
 Planned Unplanned P value 
AED use 39 (76.5%) 61 (75.3%) 0.88 
Monotherapya 31/39 (79.5%) 37/61 (60.7%) 0.049b 
VPA includeda 9/39 (23.1%) 27/61 (44.3%) 0.031b 
FA supplementation 23 (45.1%) 30 (37.0%) 0.36 
 
aMothers not receiving AEDs were excluded, bP < 0.05, AED: antiepileptic drug, VPA: 
Valproic acid, FA: Folic acid 
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Table 3: Seizure control and AEDs during pregnancy 
 
 Planned Unplanned P value 
Epileptic seizure 8 (15.7%) 28 (34.6%) 0.018a 
   AEDs after seizure    
     Increased  6  20   
     Stable 2 7  
     Discontinued 0 1b   
SUDEP 0 0 N.A 
Adjusted AEDs following pregnancy diagnosis 0 (0.0%) 21 (25.9%) < 0.001a 
   Switched 0 5  
   Decreased 0 5  
   Discontinued 0 11  
AEDs discontinued by patients themselvesc 3/39 (7.7%) 13/61 (21.3%) 0.07 
Stable dose and drugs during pregnancy 39 (76.5%) 48 (59.3%) 0.042a 
 
aP < 0.05, bA woman chose to discontinue AEDs against medical advice, cMothers not 
reaching AEDs were excluded, AED: Antiepileptic drugs, SUDEP: Sudden unexpected death 
in epilepsy 
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Table 4: Peripartum outcomes 
 
 Planned Unplanned P value 
Induced abortion 0 (0%) 4 (4.9%) 0.16 
Spontaneous abortion 2 (3.9%) 5 (6.2%) 0.71 
Stillbirth 0 (0%) 1 (1.2%) > 0.99 
Live birth 49 (96.1%) 71 (87.7%) 0.13 
PIHa 2/49 (4.1%) 3/72 (4.2%) > 0.99 
NRFSa 7/49 (14.3%) 6/72 (8.3%) 0.3 
FGRa 3/49 (6.1%) 4/72 (5.6%) > 0.99 
IUFDa 0/49 (0%) 1/72 (1.4%) > 0.99 
TOPb 9/49 (18.4%) 16/71 (22.5%) 0.58 
     Uncontrollable seizure 2 5  
     Obstetric indications 5c 8d  
     Elective 2 3  
Cesarean deliveryb 16/49 (32.7%) 23/71 (32.4%) 0.98 
     Uncontrollable seizure 0 5  
     Obstetric indications 12e 12f  
     Cerebral AVM 3 3  
     Moyamoya disease 0 1  
     Elective 1 1  
     Others 0 1  
Operative deliveryb 3/49 (6.1%) 1/71(1.4%) 0.30 
     Obstetric indications 3g 1h  
Normal vaginal deliveryb 30/49 (61.2%) 47/71 (66.2%) 0.58 
 
aCases of abortion were excluded, bCases involving stillbirths and abortions were excluded, 
cFour cases with NRFS and 1 case with FGR were included, dFour cases with FGR, 3 cases 
with NRFS, and 1 case with PIH were included, eFive cases with NRFS, 4 cases involving 
breech presentations, 1 case involving a footling presentation, 1 case involving a low-lying 
placenta, and 1 case with prior cesarean delivery were included, fThree cases with NRFS, 2 
cases involving breech presentations, 2 cases with prior cesarean delivery, 2 cases with prior 
myomectomies, 1 case of placenta previa, 1 case of obstructed labor, and 1 cases involving a 
twin pregnancy were included, gTwo cases with NRFS and 1 case of obstructed labor were 
included, hOne case with NRFS was included.  
PIH: Pregnancy-induced hypertension, NRFS: Non-reassuring fetal status, FGR: Fetal growth 
restriction, IUFD: Intra-uterine fetal death, TOP: Termination of pregnancy 
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Table 5: Neonatal outcomes 
 
 Planned Unplanneda P value 
Congenital malformationb 4/49 (8.2%) 6/74 (8.1%) > 0.99 
Birth weight (g)c 1467−3718 472−3985 0.66 
Apgar score (1 min)c 1−10 3−10 0.58 
Apgar score (5 min)c 9−10 6−10 0.11 
Withdrawal syndromec 0/49 (0%) 2/73 (2.1%) 0.52 
Neonatal hemorrhagec 0/49 (0%) 0/73 (0%) N.A. 
NICU/GCU admissionc 8/49 (16.3%) 16/73 (21.9%) 0.45 
 
aFour neonatal cases involving monochorionic, diamniotic twins were included, bCases 
involving abortions were excluded, c Cases involving stillbirths and abortions were excluded, 
N.A.: Not analyzed 
